A new cheaper version of antiviral remdesivir has been launched locally by a Indian licensee, while Chinese vaccine developers push forward with broader trials of their candidates.

As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.

Operation Warp Speed extends its funding beyond vaccines into antibodies, while insiders say friction between Moderna and US government scientists has caused delays.

Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.